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A search for antibody rises to viral antigens other than to Epstein-Barr virus, the causative
agent, has been carried out in serial serum samples from 82 patients with infectious
mononucleosis (IM). Fourfold or greater rises in titer rarely occurred and did not cluster in
time. No rises occurred to cytomegalovirus, only 1.2 percent to herpes simplex virus, and 8.5
percent to varicella zoster virus. Rises to measles antibody were found in 7.5 percent ofpatients
and to rubella in 10.4 percent; these may represent natural infections or immunizations. A few
patients also showed rises to respiratory viruses but there was no apparent connection to IM.
Acute infectious mononucleosis (IM) is accompanied by the appearance of a wide
variety of humoral antibodies in addition to those directed against the causative
agent, Epstein-Barr virus (EBV). These include: (1) heterophile antibodies, (2) cold-
reacting antibodies, (3) antibodies to Newcastle disease virus (NDV) treated human
red cells, and (4) autoantibodies (anti-muscle, anti-nuclear, anti-lymphocyte,
rheumatoid factor, etc.) [1-2]. The current study was carried out to determine if
changes in antibody titers to herpes viruses other than EBV, or to other viral
antigens, occurred during or after acute infectious mononucleosis (IM), such as that
seen in immuno-suppressed renal transplant patients [3]. Such changes might result
either from reactivation of latent agents accompanying the profound changes of
immunoregulation in acute IM [4-8] or from vigorous polyclonal expansion ofthe B
cell population [9] due in part, at least, to their infection and transformation by
EBV.
To determine possible changes in humoral antibody levels, we carried out tests
with 12 viral antigens on serial samples from cases of infectious mononucleosis.
MATERIALS AND METHODS
Patients
Only patients fulfilling clinical, hematological, and serologic criteria ofinfectious
mononucleosis were studied [10]. All were heterophil antibody positive. They con-
sisted of Yale University students or staff seen at the Yale Health Plan on whom
serial specimens had been collected by one ofus (JCN), stored at -20°C for various
periods, and then tested for viral antibodies.
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Number of Sera Available for Testing from 82 Patients with Infectious Mononucleosis
According to Time After Onset of Clinical Symptoms
Week Month
Time after onset 1 2 3 4 2 3 4 5 6 7-12 13-24 >24 Total
No. of sera 31 63 41 32 57 31 15 7 4 10 8 3 302
Antibody Tests
The following tests were employed: (1) the complement fixation (CF) test using
the 50 percent endpoint technique recommended by the National Centers for Disease
Control [11] was employed to measure antibody levels to cytomegalovirus (CMV),
herpes simplex (HSV), and varicella zoster (VZ) viruses; (2) the hemagglutination in-
hibition (HI) test for rubella was performed according to the protocol of Leibhaber
[12] and that for measles after the technique of Black [13]; (3) the indirect immuno-
fluorescence EBV-VCA antibody tests with EB3 cells followed the technique of
the Henles [14]. All sera were inactivated at 56°C for 30 minutes. Positive and
negative controls of known titer were included in each test. The CF and HI tests
were carried out on microtiter plates. Serial dilutions and the addition of reagents
were made by automated equipment produced by Cooke Engineering Co. (Alex-
andria, VA). The CF and HI antigens employed came from the National Centers for
Disease Control (Atlanta, GA), Flow Laboratories (McLean, VA), and M.A.
Bioproducts (Walkersville, MD).
Three hundred two sera from 82 IM patients were available as indicated in Ta-
ble 1. The requirements for testing were that a serum sample identified by day after
onset of clinical symptoms had been collected on thefirst visit to the physician for
infectious mononucleosis and that one or more follow-up sera were also available
for determination of rises or falls in antibody titers. Available sera from these pa-
tients were tested for antibody to herpes viruses, measles virus, and rubella virus.
One hundred forty-one sera from 36 of the same patients were tested for antibody
titers to adenovirus, parainfluenza 1, 2, and 3, and respiratory syncytial viruses. A
small sample of 29 sera from 11IM cases was tested for antibody to two influenza
antigens. In some instances there was insufficient sera to carry out all tests, and in
others technical problems (anticomplementary sera) prevented satisfactory tests. All
serial sera from apatient were tested against any one antigen at the same time to pro-
vide comparability of test results.
RESULTS
The presence or absence ofantibodyin sera taken on the initial examination ofthe
patient for IM are shown in Table 2.
About one-third had serologic evidence ofantibody to CMV, halfto HSV, and 85
percent to VZ. Almost all patients had antibody to measles (90 percent) and most to
rubella (76.9 percent). Antibodies to respiratory viruses were variously prevalent:
over 80 percent had had prior infection to parainfluenza types 1-3, 70 percent to one
or more common adenoviruses, and 90 percent to influenza virus (A/Victoria),
either from natural infection or from immunization. Antibody to RSV and to
A/New Jersey was found in only one-third of those tested.
The results ofantibody tests during illness with IM are summarized inTable 3, the
results on individual patients in Table4, and multiple antibody titers in the same pa-
204 EVANS ET AL.LACK OF NON-SPECIFIC VIRAL ANTIBODY RISES IN IM
TABLE 2
Results of Antibody Tests at Time of First Visit to Physician for Infectious Mononucleosis
No. Pts. Antibody Present
Test Tested No. 1o
Viruses of Herpes Group
Cytomegalovirus CF 65 22 33.8
Herpes Simplex CF 81 38 46.9
Varicella Zoster CF 82 70 85.4
Exanthem Viruses
Measles HI 80 72 90.0
Rubella HI 77 60 76.9
Respiratory Viruses
Adenovirus CF 36 25 69.4
Parainfluenza 1 HI 36 33 91.6
2 HI 36 29 80.5
3 HI 36 36 100.0
Respiratory Syncytial CF 36 12 33.0
Influenza A/New Jersey HI 11 4 36.4
A/Victoria HI 11 10 90.1
tient in Table 5. The timing of the rises and falls in titer in relation to the onset of
frank clinical symptoms of IM is depicted in Fig. 1.
Among herpes group antibodies other than EBV, there was remarkably little
change in titer in serial sera tested for cytomegalovirus (CMV) and herpes simplex
virus (HSV): only one patient in each group showed a rise or fall in titer. Somewhat
more common changes were found for VZ in the 82 patients tested: seven showed a
rise in titer (8.5 percent) and two a drop (2.4 percent). However, these changes in
TABLE 3
Significanta Rises or Falls in Antibody Titer to Viruses Other than EBV
During the Course of Infectious Mononucleosis
No. and % of Patients With
Number Tested
Test Rise in Titer Fall in Titer
Antibody Tested Used Patients Sera No. % No. %
Herpes Group
Cytomegalovirus CF 65 276 0 0 1 1.5
Herpes Simplex CF 81 285 1 1.2 1 1.2
Varicella Zoster CF 82 287 7 8.5 2 2.4
Exanthem
Measles HI 80 281 6 7.5 1 1.25
Rubella HI 77 280 8 10.4 8 10.4
Respiratory
Adenovirus CF 36 141 0 0 1 2.8
Parainfluenza 1 HI 36 141 1 2.8 0 0
2 HI 36 141 1 2.8 0 0
3 HI 36 141 2 5.5 1 2.8
Respiratory Syncytial CF 36 141 2 5.5 1 2.8
Influenza A/New Jers. HI 11 29 0 0 0 0
Influenza A/Victoria HI 11 29 0 0 0 0
aSignificant fourfold or greater rise or fall in titer compared with first sera
CF = Complement Fixation
HI = Hemagglutination Inhibition
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FIG. 1. Individual rises or falls of
antibody titers to 10 viruses according
to weeks of infectious mononucleosis.
titer were widely spread out after onset of acute IM symptoms (Fig. 1), ranging from
three weeks to over a year later.
Measles and rubella infections are not uncommon in the student population and
some may have received immunizations during this period. Six patients with IM
showed a rise and one a fall in titer to measles antibody; these were spread out at
various points of illness but tended to cluster in the fall months of various years
(Fig. 1). Of eight patients with an antibody rise to rubella virus, six occurred in the
first six weeks ofIM illness but were in different months or years. They may possibly
be related to immunoregulatory changes in IM.
Among seven respiratoiy antibodies tested, only one or two patients with IM
showed a rise or fall in titer (Table 3); there was no consistent temporal pattern
(Fig. 1). Infections with these viruses are not uncommon in a student population and
the results are probably unrelated to IM.
The magnitude of individual antibody rises and falls (Table 4) indicates that such
changes, while technically classified as fourfold or greater, actually represent
changes from < 10 to 20 or vice versa and may fall within technical variation.
A few patients showed multiple antibody changes (Table 5). However, there is not
very strong temporal association ofthe changes in any one patient except for patient
244, who showed rises in VZ, measles, and rubella, all occurring during the sixth
week after onset of IM.
DISCUSSION
Profound immunoregulatory changes occur during acute infectious mono-
nucleosis. There is a vigorous polyclonal expansion of B cells, leading to an increase
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TABLE 4
Actual Rises and Falls in Antibody Titer Occurring
During the Course of Infectious Mononucleosis
Patient No. Initial Titer
152 80
112 10
17 20
385 10
307 20
209 20
235 20
244 <20
112 10
17 640
144 <10
126 10
492 20
325 <10
177 10
244 20
112 20
17 40
52 40
302 20
443 <10
11 80
391 80
165 320
26 160
84 <10
1 320
95 160
244 <10
261 40
112 640
120 320
187 320
52 160
152 320
126 20
11 10
44 <10
191 80
167 20
177 40
120 10
17 20
126 < 10
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20
80
<10
40
160
<10
>160
>160
80
80
20
80
<10
20
40
80
80
160
160
<10
20
320
<10
40
640
20
40
1280
40
160
160
80
80
640
40
<10
40
20
20
80
160
40
<10
20
in immunoglobulin production and the appearance of a wide array of antibodies.
These include antibodies to various EBV antigens, the heterophil antibody, and
many antibodies of the auto-immune type, including connective tissue and anti-
nuclear antibodies [1,2]. It would seem possible that an increase in viral antibodies,
other than to EBV, might also result from this polyclonal expansion. A second
source of increase in antibody titer might be due to reactivation of latent viruses,
Antibody
CMV
HSV
Var
Measles
Rubella
Adenovirus
Parainfluenza 1
2
3
RSVTABLE 5
Multiple Rises and Falls on Same Patient
Time of Illness of
Antibody Patient No. Initial Titer Subsequent Titer Rise or Fall
HSV 112 10 80 8 months
V-Z 10 80 1 year
Rubella 640 160 8 months
Measles 20 80 1 year
HSV 17 20 <10 2 weeks
V-Z 640 80 4 months
Measles 40 160 2 weeks
RSV 20 <10 7 weeks
CMV 152 80 20 10 weeks
Rubella 320 80 11/2 years
V-Z 244 <20 >160 6 weeks
Measles 20 80 6 weeks
Rubella <10 40 6 weeks
V-Z 126 10 80 12 weeks
Adenovirus 20 <10 6 weeks
RSV <10 20 12 weeks
Measles 177 10 40 4 weeks
Parainfluenza 3 40 160 4 weeks
Measles 52 40 160 3 years
Rubella 160 640 3 months
Rubella 11 80 320 4 weeks
Parainfluenza I 10 40 11 weeks
particularly of the herpes group, that results from the changing pattern of immuno-
regulation that occurs during infectious mononucleosis. The details ofthese changes
are now emerging through the use of monoclonal antibodies and other immuno-
logical techniques [5-8,15]. Despite these two possible sources of antibody rises
from polyclonal antibody production or viral reactivation, the current study has
failed to demonstrate any concomitant antibody changes among twelve viral anti-
gens tested in serial sera obtained during and after acute IM. The few changes seen
were not clustered at any one point in illness, as one might expect if due to a com-
mon point in polyclonal B cell expansion or to changes in immunoregulation. Vari-
cella zoster showed the most change among the herpes viruses (except for EBV), but
even here only 8.5 percent of82 patients tested showed a risein titer. There were also
7.5 percent with antibody rises to rubella and 10.4 percent with antibody rises to
measles, which may well be due to natural infection and/or immunization.
Abnormal B cell proliferation occurs in the X-linked lymphoproliferative syn-
drome [16], in fatal EBV infection in children [17,18] and adults [19], and in renal
transplant patients [20]. The levels of antibodies other than EBV have not been
studied in several of these syndromes, but in renal transplant patients there is clear
evidence of reactivation of herpes viruses as indicated both by antibody rises and by
viral excretion [3,21-24]. The failure to find these changes during acute IM may be
due to the different nature, lower severity, or shorter duration of the alterations in
the immunoregulatory process in the patient with infectious mononucleosis than
those in the renal transplant recipient in whom multiple transfusions, the trans-
planted kidney, and prolonged drug-induced immunosuppression all may play a role.
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From a practical standpoint, the current studies indicate the uniqueness of the
rises ofEBV and heterophile antibodies in IM which are not therefore confused with
non-specific rises to other viral antibodies, albeit many other types ofantibodies ap-
pear. Clinically, the evidence suggests that infectious mononucleosis is not com-
monly complicated by concomitant or reactivated viral infections.
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